Triazole Antifungal Susceptibility Patterns among Aspergillus Species in Québec, Canada

J Clin Microbiol. 2019 May 24;57(6):e00404-19. doi: 10.1128/JCM.00404-19. Print 2019 Jun.

Matthew P Cheng^{1

2

3}, Alexander Lawandi⁴, Todd C Lee^{4

5}, Philippe J Dufresne⁶, Danila Seidel^{7

8}, Paul E Verweij⁹, Oliver A Cornely^{7

8

10}, Donald C Sheppard^{4

5

11}

¹ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA mcheng@bwh.harvard.edu.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
³ Harvard Medical School, Boston, Massachusetts, USA.
⁴ Division of Infectious Diseases, Department of Medicine, McGill University, Montreal, Canada.
⁵ McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Canada.
⁶ Institut National de Santé Publique du Québec, Laboratoire de Santé Publique du Québec, Montreal, Québec, Canada.
⁷ Department I of Internal Medicine, ECMM Center of Excellence for Medical Mycology, German Center for Infection Research, partner site Bonn-Cologne (DZIF), University Hospital of Cologne, Cologne, Germany.
⁸ Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
⁹ Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, the Netherlands.
¹⁰ Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.
¹¹ Department of Microbiology and Immunology, McGill University, Montreal, Canada.

No abstract available

Keywords: Aspergillus; antifungal susceptibility testing; itraconazole; posaconazole; voriconazole.

Publication types